The combination of genistein with gefitinib, a drug widely used in the treatment of various cancers, can inhibit cell proliferation and induce apoptosis in drug resistant H1975 NSCLC cells, which harbor an epidermal growth factor receptor (EGFR) mutation [126]. Here, EGFR is linked to non-small cell lung carcinoma.